Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · IEX Real-Time Price · USD
6.15
-0.23 (-3.61%)
At close: Jul 19, 2024, 4:00 PM
6.22
+0.07 (1.14%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Cytek Biosciences Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cytek Biosciences stock have an average target of 8.63, with a low estimate of 7.00 and a high estimate of 10. The average target predicts an increase of 40.33% from the current stock price of 6.15.
Analyst Consensus: Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for CTKB stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $10 → $8.5 | Buy | Maintains | $10 → $8.5 | +38.21% | May 13, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $11 → $10 | Buy | Maintains | $11 → $10 | +62.60% | Mar 6, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +62.60% | Feb 29, 2024 |
| Stephens & Co. | Stephens & Co. | Buy Initiates $9 | Buy | Initiates | $9 | +46.34% | Dec 14, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $8 → $7 | Hold | Maintains | $8 → $7 | +13.82% | Nov 9, 2023 |
Financial Forecast
Revenue This Year
212.98M
from 193.02M
Increased by 10.34%
Revenue Next Year
252.43M
from 212.98M
Increased by 18.52%
EPS This Year
-0.06
from -0.09
EPS Next Year
0.07
from -0.06
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 222.0M | 280.1M | 324.0M |
| Avg | 213.0M | 252.4M | 284.2M |
| Low | 200.6M | 224.7M | 242.5M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 15.0% | 31.5% | 28.3% |
| Avg | 10.3% | 18.5% | 12.6% |
| Low | 3.9% | 5.5% | -3.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | 0.19 | 0.15 |
| Avg | -0.06 | 0.07 | 0.11 |
| Low | -0.11 | -0.02 | 0.07 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | 125.2% |
| Avg | - | - | 66.7% |
| Low | - | - | 5.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.